The influence of hormone therapies on colon and rectal cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The influence of hormone therapies on colon and rectal cancer. / Mørch, Lina Steinrud; Lidegaard, Øjvind; Keiding, Niels; Løkkegaard, Ellen; Kjær, Susanne Krüger.
In: European Journal of Epidemiology, Vol. 31, No. 5, 05.2016, p. 481-489.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The influence of hormone therapies on colon and rectal cancer
AU - Mørch, Lina Steinrud
AU - Lidegaard, Øjvind
AU - Keiding, Niels
AU - Løkkegaard, Ellen
AU - Kjær, Susanne Krüger
PY - 2016/5
Y1 - 2016/5
N2 - Exogenous sex hormones seem to play a role in colorectal carcinogenesis. Little is known about the influence of different types or durations of postmenopausal hormone therapy (HT) on colorectal cancer risk. A nationwide cohort of women 50–79 years old without previous cancer (n = 1,006,219) were followed 1995–2009. Information on HT exposures was from the National Prescription Register and updated daily, while information on colon (n = 8377) and rectal cancers (n = 4742) were from the National Cancer Registry. Potential confounders were obtained from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates. Use of estrogen-only therapy and combined therapy were associated with decreased risks of colon cancer (adjusted incidence rate ratio 0.77, 95 % confidence interval 0.68–0.86 and 0.88, 0.80–0.96) and rectal cancer (0.83, 0.72–0.96 and 0.89, 0.80–1.00), compared to never users. Transdermal estrogen-only therapy implied more protection than oral administration, while no significant influence was found of regimen, progestin type, nor of tibolone. The benefit of HT was stronger for long-term hormone users; and hormone users were at lower risk of advanced stage of colorectal cancer, which seems supportive for a causal association between hormone therapy and colorectal cancer.
AB - Exogenous sex hormones seem to play a role in colorectal carcinogenesis. Little is known about the influence of different types or durations of postmenopausal hormone therapy (HT) on colorectal cancer risk. A nationwide cohort of women 50–79 years old without previous cancer (n = 1,006,219) were followed 1995–2009. Information on HT exposures was from the National Prescription Register and updated daily, while information on colon (n = 8377) and rectal cancers (n = 4742) were from the National Cancer Registry. Potential confounders were obtained from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates. Use of estrogen-only therapy and combined therapy were associated with decreased risks of colon cancer (adjusted incidence rate ratio 0.77, 95 % confidence interval 0.68–0.86 and 0.88, 0.80–0.96) and rectal cancer (0.83, 0.72–0.96 and 0.89, 0.80–1.00), compared to never users. Transdermal estrogen-only therapy implied more protection than oral administration, while no significant influence was found of regimen, progestin type, nor of tibolone. The benefit of HT was stronger for long-term hormone users; and hormone users were at lower risk of advanced stage of colorectal cancer, which seems supportive for a causal association between hormone therapy and colorectal cancer.
KW - Colon cancer
KW - Rectum cancer
KW - Hormone replacement therapy
KW - Types of hormone therapy
KW - Stage of disease
U2 - 10.1007/s10654-016-0116-z
DO - 10.1007/s10654-016-0116-z
M3 - Journal article
C2 - 26758900
VL - 31
SP - 481
EP - 489
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
SN - 0393-2990
IS - 5
ER -
ID: 163194801